Christopher R. Ellis, MD, FACC, FHRS completed medical school at University of Rochester, NY in 2000. He completed Cardiovascular Medicine Fellowship at Vanderbilt University Medical Center in 2008, and Clinical Cardiac Electrophysiology Fellowship at University of Michigan before re-joining Vanderbilt Heart and Vascular Institute in July 2009. He is currently Professor of Medicine and Director of the Atrial Fibrillation Center and LAA program. His academic focus within Atrial Fibrillation (AF) has focused on the role of the Left Atrial Appendage (LAA) in AF related stroke, and treatment options to reduce dependence on oral anti-coagulation for stroke risk reduction. With a broad experience performing over > 2000 LAAC cases since 2012, Dr. Ellis has helped advance LAA therapy as a key opinion leader, top implanter for the Amulet IDE trial, executive committee guidance and top enroller for LARIAT and the AMAZE trial, and the CONFORMAL IDE. He currently is enrolling in CATALYST, CHAMPION, CONFORMAL IDE, LAMINAR IDE and Veritas IDE (Amulet II) clinical trials. As a high volume AF ablation expert he has helped develop hybrid AF ablation therapy and now novel PFA therapy through the ADVENT trial, ADVANTAGE AF, and OPTION with extensive experience and guiding best practices in concomitant AF ablation with LAAC procedures.